Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 61

1.

Aspergiolides C and D: spirocyclic aromatic polyketides with potent protein kinase c-Met inhibitory effects.

Du L, Ai J, Li D, Zhu T, Wang Y, Knauer M, Bruhn T, Liu H, Geng M, Gu Q, Bringmann G.

Chemistry. 2011 Jan 24;17(4):1319-26. doi: 10.1002/chem.201001547. Epub 2010 Dec 3.

PMID:
21243700
2.

BMS-777607, a small-molecule met kinase inhibitor, suppresses hepatocyte growth factor-stimulated prostate cancer metastatic phenotype in vitro.

Dai Y, Siemann DW.

Mol Cancer Ther. 2010 Jun;9(6):1554-61. doi: 10.1158/1535-7163.MCT-10-0359. Epub 2010 Jun 1.

3.

Structural and functional basis of the serine protease-like hepatocyte growth factor beta-chain in Met binding and signaling.

Kirchhofer D, Yao X, Peek M, Eigenbrot C, Lipari MT, Billeci KL, Maun HR, Moran P, Santell L, Wiesmann C, Lazarus RA.

J Biol Chem. 2004 Sep 17;279(38):39915-24. Epub 2004 Jun 24.

6.

Inhibition of tumor cell growth, invasion, and metastasis by EXEL-2880 (XL880, GSK1363089), a novel inhibitor of HGF and VEGF receptor tyrosine kinases.

Qian F, Engst S, Yamaguchi K, Yu P, Won KA, Mock L, Lou T, Tan J, Li C, Tam D, Lougheed J, Yakes FM, Bentzien F, Xu W, Zaks T, Wooster R, Greshock J, Joly AH.

Cancer Res. 2009 Oct 15;69(20):8009-16. doi: 10.1158/0008-5472.CAN-08-4889. Epub 2009 Oct 6.

7.

A peptide representing the carboxyl-terminal tail of the met receptor inhibits kinase activity and invasive growth.

Bardelli A, Longati P, Williams TA, Benvenuti S, Comoglio PM.

J Biol Chem. 1999 Oct 8;274(41):29274-81.

8.

Mechanisms of hepatocyte growth factor-induced retinal endothelial cell migration and growth.

Cai W, Rook SL, Jiang ZY, Takahara N, Aiello LP.

Invest Ophthalmol Vis Sci. 2000 Jun;41(7):1885-93.

PMID:
10845613
10.

Identification of functional domains in the hepatocyte growth factor and its receptor by molecular engineering.

Bardelli A, Ponzetto C, Comoglio PM.

J Biotechnol. 1994 Sep 30;37(2):109-22. Review.

PMID:
7765452
11.

Noncompetitive inhibition of hepatocyte growth factor-dependent Met signaling by a phage-derived peptide.

Tam EM, Runyon ST, Santell L, Quan C, Yao X, Kirchhofer D, Skelton NJ, Lazarus RA.

J Mol Biol. 2009 Jan 9;385(1):79-90. doi: 10.1016/j.jmb.2008.09.091. Epub 2008 Oct 15.

PMID:
18973760
12.

Modulation of the c-Met/hepatocyte growth factor pathway in small cell lung cancer.

Maulik G, Kijima T, Ma PC, Ghosh SK, Lin J, Shapiro GI, Schaefer E, Tibaldi E, Johnson BE, Salgia R.

Clin Cancer Res. 2002 Feb;8(2):620-7.

13.

A selective c-met inhibitor blocks an autocrine hepatocyte growth factor growth loop in ANBL-6 cells and prevents migration and adhesion of myeloma cells.

Hov H, Holt RU, Rø TB, Fagerli UM, Hjorth-Hansen H, Baykov V, Christensen JG, Waage A, Sundan A, Børset M.

Clin Cancer Res. 2004 Oct 1;10(19):6686-94.

14.
15.

c-Met is a potentially new therapeutic target for treatment of human melanoma.

Puri N, Ahmed S, Janamanchi V, Tretiakova M, Zumba O, Krausz T, Jagadeeswaran R, Salgia R.

Clin Cancer Res. 2007 Apr 1;13(7):2246-53.

16.

MK-2461, a novel multitargeted kinase inhibitor, preferentially inhibits the activated c-Met receptor.

Pan BS, Chan GK, Chenard M, Chi A, Davis LJ, Deshmukh SV, Gibbs JB, Gil S, Hang G, Hatch H, Jewell JP, Kariv I, Katz JD, Kunii K, Lu W, Lutterbach BA, Paweletz CP, Qu X, Reilly JF, Szewczak AA, Zeng Q, Kohl NE, Dinsmore CJ.

Cancer Res. 2010 Feb 15;70(4):1524-33. doi: 10.1158/0008-5472.CAN-09-2541. Epub 2010 Feb 9.

17.

Tyrosine phosphorylation of p145met mediated by EGFR and Src is required for serum-independent survival of human bladder carcinoma cells.

Yamamoto N, Mammadova G, Song RX, Fukami Y, Sato K.

J Cell Sci. 2006 Nov 15;119(Pt 22):4623-33. Epub 2006 Oct 24.

18.

The N-terminal domain of hepatocyte growth factor inhibits the angiogenic behavior of endothelial cells independently from binding to the c-met receptor.

Merkulova-Rainon T, England P, Ding S, Demerens C, Tobelem G.

J Biol Chem. 2003 Sep 26;278(39):37400-8. Epub 2003 Jul 7.

20.

Adaptor molecule Crk is required for sustained phosphorylation of Grb2-associated binder 1 and hepatocyte growth factor-induced cell motility of human synovial sarcoma cell lines.

Watanabe T, Tsuda M, Makino Y, Ichihara S, Sawa H, Minami A, Mochizuki N, Nagashima K, Tanaka S.

Mol Cancer Res. 2006 Jul;4(7):499-510.

Supplemental Content

Support Center